glycyrrhetinic acid has been researched along with celastrol in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brooks, WH; Chen, L; Daniel, KG; Guida, WC; Lawrence, HR; Lawrence, NJ; Scott, LM; Sebti, SM; Wu, J | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Huang, R; Huang, X; Ji, M; Jin, L; Wang, H; Zhang, B | 1 |
| Song, Y; Wang, S; Yang, X; Yu, B; Zhao, M | 1 |
| Chang, YH; Hung, HY | 1 |
2 review(s) available for glycyrrhetinic acid and celastrol
| Article | Year |
|---|---|
Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Discovery; Enzyme Inhibitors; Humans; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 2022 |
Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: A mini-review.
Topics: Animals; Anti-Obesity Agents; Drug Discovery; Obesity; Phytochemicals | 2022 |
3 other study(ies) available for glycyrrhetinic acid and celastrol
| Article | Year |
|---|---|
Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.
Topics: Antineoplastic Agents, Hormonal; Estramustine; Humans; Models, Molecular; Neoplasms; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Structure-Activity Relationship; Triterpenes | 2011 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
Topics: Antineoplastic Agents; Apoptosis; Benzothiazoles; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chaperonins; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glycyrrhetinic Acid; HSP90 Heat-Shock Proteins; Humans; Molecular Structure; Structure-Activity Relationship | 2018 |